Compare Novo Nordisk A/S (NVO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PubMatic Inc — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while PubMatic Inc trades at $16.19 (market cap $736.54M). The key difference: Novo Nordisk A/S is far larger — about 269.6× PubMatic Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| NVO | PUBM | |
|---|---|---|
Market Cap | $198.57B | $736.54M |
Sector | Health | Technology |
52-Week High | $63.98 | $17.78 |
52-Week Low | $35.29 | $6.28 |
Enterprise Value | $213.37B | $639.67M |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
PUBM trades at $16.29, down 1.27% on the day, with a bullish technical signal supported by moving averages and recent crossing above the 20-day average. The company reported Q2 2026 revenue growth of 10.5% year-over-year and an EPS beat, driven by mobile app and CTV segments. Analyst consensus is strongly positive with 11 buy ratings and a $20.83 price target, implying 28% upside from current levels.
The outlook is cautiously optimistic given strong revenue momentum and AI product adoption, but negative net margins and high P/E of 132 pose valuation risks. Key catalysts include continued execution in high-margin segments and leadership transitions, while competitive pressures and macroeconomic headwinds remain concerns for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
